BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - FRA:IDP - US09062X1037 - Common Stock
133 EUR
-1.45 (-1.08%)
Taking everything into account, IDP scores 6 out of 10 in our fundamental rating. IDP was compared to 74 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making IDP a very profitable company, without any liquidiy or solvency issues. IDP is cheap, but on the other hand it scores bad on growth. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year IDP was profitable.
In the past year IDP had a positive cash flow from operations.
In the past 5 years IDP has always been profitable.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.51%, IDP belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
IDP has a better Return On Equity (8.83%) than 84.21% of its industry peers.
IDP has a better Return On Invested Capital (9.70%) than 88.16% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 12.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.83% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
IDP has a Profit Margin of 15.98%. This is amongst the best in the industry. IDP outperforms 85.53% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
The Operating Margin of IDP (28.50%) is better than 88.16% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
IDP has a better Gross Margin (75.24%) than 69.74% of its industry peers.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
IDP has more shares outstanding than it did 1 year ago.
IDP has less shares outstanding than it did 5 years ago.
IDP has a better debt/assets ratio than last year.
2.2 Solvency
IDP has an Altman-Z score of 3.12. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
IDP has a better Altman-Z score (3.12) than 76.32% of its industry peers.
The Debt to FCF ratio of IDP is 2.78, which is a good value as it means it would take IDP, 2.78 years of fcf income to pay off all of its debts.
IDP's Debt to FCF ratio of 2.78 is amongst the best of the industry. IDP outperforms 84.21% of its industry peers.
IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
IDP has a Debt to Equity ratio (0.35) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.12 |
ROIC/WACC1.2
WACC8.08%
2.3 Liquidity
IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IDP (2.72) is comparable to the rest of the industry.
A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
The Quick ratio of IDP (2.04) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.52% on average over the next years.
Based on estimates for the next years, IDP will show a decrease in Revenue. The Revenue will decrease by -0.65% on average per year.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.19, the valuation of IDP can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 92.11% of the companies listed in the same industry.
IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.06.
A Price/Forward Earnings ratio of 9.85 indicates a reasonable valuation of IDP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 97.37% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (32.73), we can say IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.19 | ||
| Fwd PE | 9.85 |
4.2 Price Multiples
90.79% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 92.11% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.97 | ||
| EV/EBITDA | 6.82 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (11/7/2025, 7:00:00 PM)
133
-1.45 (-1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap19.50B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target150.4 (13.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)1.52%
PT rev (3m)1.03%
EPS NQ rev (1m)-54.54%
EPS NQ rev (3m)-55.25%
EPS NY rev (1m)-4.15%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.22%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.19 | ||
| Fwd PE | 9.85 | ||
| P/S | 2.24 | ||
| P/FCF | 9.97 | ||
| P/OCF | 9.19 | ||
| P/B | 1.24 | ||
| P/tB | 9.45 | ||
| EV/EBITDA | 6.82 |
EPS(TTM)14.48
EY10.89%
EPS(NY)13.51
Fwd EY10.15%
FCF(TTM)13.35
FCFY10.03%
OCF(TTM)14.48
OCFY10.88%
SpS59.39
BVpS107.42
TBVpS14.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number187.08
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.83% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.45% | ||
| ROICexgc | 40.97% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.08% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.54% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.12 |
F-Score5
WACC8.08%
ROIC/WACC1.2
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.19%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.46%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.45%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -5.79% in the next year.